Ocular reports Phase II glaucoma data for travoprost plug

Ocular Therapeutix Inc. (Bedford, Mass.) reported top-line data from a Phase II trial to treat glaucoma showing that OTX-TP2 led to a reduction in mean intraocular pressure (IOP) of 6.8 mmHg from baseline to day 60. Additionally, OTX-TP2 reduced mean IOP by 7.2 mmHg from baseline to day 15, by 6.6 mmHg at day 30 and by 6.7 mmHg at day 45. Mean IOP at baseline was 28.7 mmHg. Ocular Therapeutix, which did not conduct statistical testing for the reductions in IOP, also said the results were comparable to that observed with the marketed topical ophthalmic solutions. The open-label, South African Phase II trial evaluated OTX-TP2 in 36 eyes from 20 patients with open-angle glaucoma or ocular hypertension. The company plans to start a Phase III trial of OTX-TP2 by the end of 2014. ...